NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis $1.68 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.04 (+2.32%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gain Therapeutics Stock (NASDAQ:GANX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gain Therapeutics alerts:Sign Up Key Stats Today's Range$1.64▼$1.7150-Day Range$1.58▼$2.1452-Week Range$1.41▼$4.34Volume482,863 shsAverage Volume713,001 shsMarket Capitalization$71.65 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingModerate Buy Company Overview Gain Therapeutics, Inc. (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects. Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity. In addition to its clinical program, the company is advancing preclinical pipelines targeting Parkinson’s disease and other central nervous system disorders. Using structure-based design and high-throughput screening, Gain seeks to expand its pipeline across multiple indications with high unmet medical need. Headquartered in Geneva, Switzerland, with research operations in Massachusetts, Gain Therapeutics was founded in 2015 and has since established collaborations with academic centers and industry partners to support its discovery and development efforts. The company is led by a management team with experience in biotechnology, pharmaceutical development, and protein science, guiding Gain through translational research toward clinical validation.AI Generated. May Contain Errors. Read More Gain Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreGANX MarketRank™: Gain Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 649th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingGain Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialGain Therapeutics has a consensus price target of $8.50, representing about 406.0% upside from its current price of $1.68.Amount of Analyst CoverageGain Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Gain Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gain Therapeutics are expected to decrease in the coming year, from ($0.54) to ($0.60) per share.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gain Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.82% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 3.86, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently increased by 1.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.64 News SentimentGain Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Gain Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for GANX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.15% of the stock of Gain Therapeutics is held by insiders.Percentage Held by Institutions11.97% of the stock of Gain Therapeutics is held by institutions.Read more about Gain Therapeutics' insider trading history. Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GANX Stock News HeadlinesGain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitJune 10 at 7:00 AM | globenewswire.comGain Therapeutics (GANX) Receives a Buy from H.C. WainwrightJune 9 at 6:03 PM | theglobeandmail.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 12 at 1:00 AM | Porter & Company (Ad)Esperion Therapeutics (NASDAQ:ESPR) and Gain Therapeutics (NASDAQ:GANX) Critical SurveyJune 4, 2026 | americanbankingnews.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of "Moderate Buy" from BrokeragesJune 1, 2026 | americanbankingnews.comFY2026 EPS Estimate for Gain Therapeutics Lowered by AnalystJune 1, 2026 | americanbankingnews.comGain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidateMay 27, 2026 | finance.yahoo.comGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026May 26, 2026 | globenewswire.comSee More Headlines GANX Stock Analysis - Frequently Asked Questions How have GANX shares performed this year? Gain Therapeutics' stock was trading at $3.22 at the start of the year. Since then, GANX stock has decreased by 47.8% and is now trading at $1.68. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.13). When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,636,364 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Gain Therapeutics' major shareholders? Gain Therapeutics' top institutional investors include Apollon Wealth Management LLC (0.06%). Insiders that own company stock include Eric I Richman, Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder. View institutional ownership trends. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gain Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings5/11/2026Today6/12/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 GANX's financial health is in the Yellow zone, according to TradeSmith. GANX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GANX CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees20Year Founded2017Price Target and Rating Average Price Target for Gain Therapeutics$8.50 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+406.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-201.44% Return on Assets-136.24% Debt Debt-to-Equity Ratio0.02 Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual Sales$50 thousand Price / Sales1,433.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.50Miscellaneous Outstanding Shares42,650,000Free Float40,884,000Market Cap$71.65 million OptionableOptionable Beta0.16 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:GANX) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThere’s a new type of capitalismThe U.S. government has taken direct equity positions in at least 10 companies - Intel, U.S. Steel, Westinghou...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
